GlassScriptPhysician profile
Amy L Schuldt
NPI 1831447986
$5,224.74
in general payments reported to CMS, 2019-2025
43 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what 97% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $924 · 2022: $740 · 2023: $802 · 2024: $1,424 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,560.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.87 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $475.78 | 2021-2025 | |
| Pfizer INC. | $300.90 | 2022-2025 | |
| Glaxosmithkline, LLC. | $269.61 | 2022-2025 | Bexsero, Rotarix, Shingrix |
| Lilly USA, LLC | $263.02 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $213.10 | 2024-2025 | Airsupra |
| Cranial Technologies, INC | $192.91 | 2023-2025 | Doc Band |
| Ironwood Pharmaceuticals, INC | $182.56 | 2024 | |
| Nestle Healthcare Nutrition INC. | $165.34 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $134.01 | 2024-2025 | Zenpep |
| Hologic Sales and Service, LLC | $129.77 | 2025 | Aptima |
| Novo Nordisk INC | $94.43 | 2023-2025 | Ozempic, Wegovy |
| Exact Sciences Corporation | $91.13 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $88.10 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.16 | 2021-2023 | Xifaxan |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $78.10 | 2021 | |
| Exeltis, USA INC. | $70.92 | 2022-2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $66.80 | 2021 | |
| Lundbeck LLC | $57.44 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $56.83 | 2021-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Alnylam Pharmaceuticals INC. | $48.56 | 2021-2023 | Onpattro |
| Dexcom, INC. | $43.47 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $39.29 | 2023-2024 | Gvoke Hypopen |
| Eisai INC. | $37.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.41 | 2022 | |
| Gilead Sciences, INC. | $33.13 | 2025 | |
| Vanda Pharmaceuticals INC. | $30.43 | 2024 | Fanapt |
| Qol Medical, LLC | $30.03 | 2024 | Sucraid |
| Ani Pharmaceuticals, INC. | $29.92 | 2025 | Purified Cortrophin Gel |
| Agile Therapeutics, INC. | $27.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.36 | 2021 | |
| Daiichi Sankyo INC. | $24.21 | 2023 | Injectafer |
| Pulmonx Corporation | $22.66 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.41 | 2025 | Caplyta |
| Seqirus USA INC | $21.07 | 2025 | Flucelvax, Fluad |
| Paratek Pharmaceuticals, INC. | $20.48 | 2024 | Nuzyra |
| Davol INC. | $18.53 | 2021 | |
| Sanofi Pasteur INC. | $17.20 | 2021 | |
| Mayne Pharma Commercial LLC | $16.16 | 2023 | |
| Viiv Healthcare Company | $15.21 | 2024 | Apretude |
| Insulet Corporation | $14.77 | 2024 | Omnipod |
| Travere Therapeutics, INC. | $14.28 | 2022 | |
| Ibsa Pharma INC. | $13.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Schuldt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.